215 related articles for article (PubMed ID: 23540593)
1. Rituximab in the treatment of primary cutaneous B-cell lymphoma: a review.
Fernández-Guarino M; Ortiz-Romero PL; Fernández-Misa R; Montalbán C
Actas Dermosifiliogr; 2014 Jun; 105(5):438-45. PubMed ID: 23540593
[TBL] [Abstract][Full Text] [Related]
2. Rituximab plus liposomal pegylated doxorubicin in the treatment of primary cutaneous B-cell lymphomas.
Fabbri A; Cencini E; Alterini R; Rubegni P; Rigacci L; Delfino C; Puccini B; Fimiani M; Bosi A; Bocchia M; Pimpinelli N;
Eur J Haematol; 2014 Aug; 93(2):129-36. PubMed ID: 24635751
[TBL] [Abstract][Full Text] [Related]
3. Spontaneous regression of primary diffuse large B-cell lymphoma, leg type.
Alcántara-González J; González-García C; Fernández-Guarino M; Jaén-Olasolo P
Actas Dermosifiliogr; 2014; 105(1):78-83. PubMed ID: 23098572
[TBL] [Abstract][Full Text] [Related]
4. Long-term outcome of intravenous therapy with rituximab in patients with primary cutaneous B-cell lymphomas.
Brandenburg A; Humme D; Terhorst D; Gellrich S; Sterry W; Beyer M
Br J Dermatol; 2013 Nov; 169(5):1126-32. PubMed ID: 23796422
[TBL] [Abstract][Full Text] [Related]
5. [Cutaneous follicular center B-cell lymphoma treated with intralesional rituximab].
Gamo R; Calzado L; Pinedo F; López-Estebaranz JL
Actas Dermosifiliogr; 2008 May; 99(4):291-6. PubMed ID: 18394405
[TBL] [Abstract][Full Text] [Related]
6. Focal rituximab-induced edematous reaction at primary cutaneous follicle center lymphoma lesions: case report and literature review.
Brunet-Possenti F; Franck N; Tamburini J; Jacobelli S; Avril MF; Dupin N
Dermatology; 2011; 223(3):200-2. PubMed ID: 21986026
[TBL] [Abstract][Full Text] [Related]
7. Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas--an applicational observation.
Gellrich S; Muche JM; Wilks A; Jasch KC; Voit C; Fischer T; Audring H; Sterry W
Br J Dermatol; 2005 Jul; 153(1):167-73. PubMed ID: 16029344
[TBL] [Abstract][Full Text] [Related]
8. Complete remission of a primary cutaneous B-cell lymphoma of the lower leg by first-line monotherapy with the CD20-antibody rituximab.
Bonnekoh B; Schulz M; Franke I; Gollnick H
J Cancer Res Clin Oncol; 2002 Mar; 128(3):161-6. PubMed ID: 11935303
[TBL] [Abstract][Full Text] [Related]
9. Treatment of radiation-relapsing primary cutaneous B-cell lymphoma with an anti-CD20 monoclonal antibody.
Lacouture ME; Baron JM; Jani AB; Laumann AE; Soltani K
Clin Exp Dermatol; 2005 Jan; 30(1):46-8. PubMed ID: 15663503
[TBL] [Abstract][Full Text] [Related]
10. Primary cutaneous B-cell lymphomas.
Kempf W; Denisjuk N; Kerl K; Cozzio A; Sander C
J Dtsch Dermatol Ges; 2012 Jan; 10(1):12-22; quiz 23. PubMed ID: 22212142
[TBL] [Abstract][Full Text] [Related]
11. Intralesional and intravenous treatment of cutaneous B-cell lymphomas with the monoclonal anti-CD20 antibody rituximab: report and follow-up of eight cases.
Kerl K; Prins C; Saurat JH; French LE
Br J Dermatol; 2006 Dec; 155(6):1197-200. PubMed ID: 17107389
[TBL] [Abstract][Full Text] [Related]
12. Rituximab in cutaneous B-cell lymphoma: a report of two cases.
Sabroe RA; Child FJ; Woolford AJ; Spittle MF; Russell-Jones R
Br J Dermatol; 2000 Jul; 143(1):157-61. PubMed ID: 10886152
[TBL] [Abstract][Full Text] [Related]
13. Recent advances in primary cutaneous B-cell lymphomas.
Vermeer MH; Willemze R
Curr Opin Oncol; 2014 Mar; 26(2):230-6. PubMed ID: 24463347
[TBL] [Abstract][Full Text] [Related]
14. [Cutaneous B-cell lymphoma treatment with rituximab: two cases].
Viguier M; Bachelez H; Brice P; Rivet J; Dubertret L
Ann Dermatol Venereol; 2002 Oct; 129(10 Pt 1):1152-5. PubMed ID: 12442128
[TBL] [Abstract][Full Text] [Related]
15. Treatment of primary cutaneous follicular centre lymphoma with rituximab: a report of two cases.
Kennedy GA; Blum R; McCormack C; Prince HM
Australas J Dermatol; 2004 Feb; 45(1):34-7. PubMed ID: 14961906
[TBL] [Abstract][Full Text] [Related]
16. Intralesional rituximab in the treatment of indolent primary cutaneous B-cell lymphomas: an epidemiological observational multicentre study. The Spanish Working Group on Cutaneous Lymphoma.
Peñate Y; Hernández-Machín B; Pérez-Méndez LI; Santiago F; Rosales B; Servitje O; Estrach T; Fernández-Guarino M; Calzado L; Acebo E; Gallardo F; Salar A; Izu R; Ortiz-Romero PL; Pujol RM; Fernández-de-Misa R
Br J Dermatol; 2012 Jul; 167(1):174-9. PubMed ID: 22356294
[TBL] [Abstract][Full Text] [Related]
17. Indolent primary cutaneous B-cell lymphoma: experience using systemic rituximab.
Morales AV; Advani R; Horwitz SM; Riaz N; Reddy S; Hoppe RT; Kim YH
J Am Acad Dermatol; 2008 Dec; 59(6):953-7. PubMed ID: 18817999
[TBL] [Abstract][Full Text] [Related]
18. [Management of cutaneous B-cell lymphoma: recommendations of the French cutaneous lymphoma study group].
Grange F; D'Incan M; Ortonne N; Dalac S; Laroche L; Beylot-Barry M; Delfau-Larue MH; Vergier B; Bagot M;
Ann Dermatol Venereol; 2010; 137(8-9):523-31. PubMed ID: 20804896
[TBL] [Abstract][Full Text] [Related]
19. Reduction of tumor burden and stabilization of disease by systemic therapy with anti-CD20 antibody (rituximab) in patients with primary cutaneous B-cell lymphoma.
Heinzerling LM; Urbanek M; Funk JO; Peker S; Bleck O; Neuber K; Burg G; von Den Driesch P; Dummer R
Cancer; 2000 Oct; 89(8):1835-44. PubMed ID: 11042581
[TBL] [Abstract][Full Text] [Related]
20. Regression of cutaneous intravascular lymphoma with rituximab.
Han K; Haley JC; Carlson K; Pinter-Brown L; Soriano T
Cutis; 2003 Aug; 72(2):137-40. PubMed ID: 12953938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
